<DOC>
	<DOCNO>NCT00623805</DOCNO>
	<brief_summary>This 2 arm study assess efficacy safety maintenance treatment Avastin ( bevacizumab ) + Xeloda ( capecitabine ) , initial treatment Xeloda + oxaliplatin + Avastin , patient metastatic colorectal cancer . Patients randomize one 2 group receive 1 ) Xeloda + oxaliplatin + Avastin disease progression 2 ) Xeloda + oxaliplatin + Avastin 6 3-week cycle , follow Xeloda + Avastin disease progression . Xeloda administer dose 1000 mg/m^2 orally twice day day 1-14 cycle , oxaliplatin dose 130 mg/m^2 intravenously ( iv ) day 1 cycle , Avastin dose 7.5 mg/kg iv day 1 cycle .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Xeloda ( Capecitabine ) Maintenance Treatment Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Adult patient , â‰¥ 18 year age . Histologically confirm colon rectal cancer , unresectable metastatic disease . At least 1 measurable lesion . Outpatient , Eastern Cooperative Oncology Group ( ECOG ) Performance Status = 01 . Previous treatment Avastin . Previous systemic treatment advance metastatic disease . clinically significant cardiovascular disease . Daily chronic treatment high dos aspirin ( &gt; 325 mg/day ) nonsteroidal antiinflammatory drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>